While the momentum behind value- and outcomes-based contracts is picking up steam, the reality is that the road ahead remains a long, bumpy ride, according to an article published in Forbes.
According to the article, about 30 percent of healthcare payments in 2016 in hospital and outpatient clinic settings were conducted through alternative payment models, including shared savings, risk-sharing arrangements and population-based reimbursement.
Operational barriers are playing a significant role in the slower-than-anticipated widespread implementation of value-based payment models, however.
“Today, approximately 25 branded drugs are subject to some form of value- or outcomes-based contracting in the U.S.,” the author, healthcare analyst Joshua Cohen, writes. “But, most contracts are ‘limited in applicability to disease states with more standardized protocols and dominated by drug therapies with single indications — notably osteoporosis, diabetes and hepatitis C.'”